Coadministration of Isoniazid and Antidepressant Drugs
J Clin Psychiatry 1996;57(11):550 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Isonicotinylhydrazide, also known as isoniazid, is a
well-known agent for treatment of mycobacterial infections. It
is also used for prevention of tuberculosis, given 300 mg/day
for a period of at least 6 months. In vivo studies, using
benzylamine as substrate, have demonstrated that isoniazid in
therapeutic doses inhibits plasma monoamine oxidase (MAO)
with no significant effect on platelet MAO.